Joshua Woolley, MD, PhD
This is an open-label, single-arm, pilot study exploring the neural, sensory, and cognitive effects of a single, medium dose of psilocybin in patients with chronic pain who already have implanted sensing-capable deep brain stimulation (DBS) devices. Outcomes include multi-site neural recording from previously placed ambulatory sensing-capable DBS devices, quantitative sensory and cognitive testing, and self-reports of pain. We hypothesize that psilocybin will change functional connectivity, decrease clinical and task-based pain reports, and improve cognitive functions.
This is an open-label, single-arm, pilot study exploring the neural, sensory, and cognitive effects of a single, medium dose of psilocybin in patients with chronic pain who already have implanted sensing-capable deep brain stimulation (DBS) devices. Outcomes include multi-site neural recording from previously placed ambulatory sensing-capable DBS devices, quantitative sensory and cognitive testing, and self-reports of pain. We hypothesize that psilocybin will change functional connectivity, decrease clinical and task-based pain reports, and improve cognitive functions.
Inclusion Criteria: * Currently implanted chronic brain sensing device (such as RC+S or Percept) * Not currently enrolled in another trial * Ability to speak and read English * Able to attend all in-person and virtual visits * No changes in medication or major surgical procedures anticipated for the trial * Able to identify someone to accompany from the research unit at the end of drug administration day or agreement to have a study team member accompany them from the research unit Exclusion Criteria: * A health condition that makes this study unsafe or unfeasible, determined by study physi…
10mg oral psilocybin
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.